With many weight loss medications to choose from, semaglutide is a notable option. Approved by the U.S. Food and Drug Administration in 2021, this medication has gained popularity as an anti-obesity ingredient.
Although originally developed for diabetes, it has since been approved for long-term weight management. It is the first drug since Saxenda in 2014 to be approved for the treatment of obesity. This suggests a shift in approaching obesity as a chronic metabolic disease, as people choose alternatives other than relying solely on lifestyle changes and motivation.
Understanding Semaglutide
Semaglutide belongs to the class of glucagon-like peptide-1 receptor agonists (GLP-1 RAs). It mimics the hormone GLP-1, which is released in response to food intake. GLP-1 increases insulin production and lowers blood sugar levels.
This dual action of both glucose control and appetite suppression makes semaglutide a powerful tool for weight loss, especially when combined with dietary and exercise modifications. It can dramatically reduce the risks associated with obesity, such as heart disease, cancer, and diabetes.
Application in Weight Loss
Currently, semaglutide is marketed under the brand name Wegovy for weight loss. The recommended dose is 2.4 milligrams injected weekly. However, because of its popularity, other brands of semaglutide, such as Ojempic and Rybelsus, have also been prescribed off-label for weight management. This increased demand has created shortages, particularly affecting diabetic patients in need of the drug.
Studies have consistently demonstrated the efficacy of semaglutide in weight management. Initial studies involving 2,000 obese adults showed that semaglutide administration, in combination with diet and exercise, resulted in significant weight loss compared with controls relying solely on lifestyle changes.
However, stopping the medication can lead to weight regain, and therefore lifestyle changes will need to be maintained.
Side Effects Of Semaglutide
People taking semaglutide as part of a weight loss regimen may experience side effects, which, although usually manageable, are important to consider. These include:
- Dizziness
- Fatigue
- Gastrointestinal discomfort
- Headaches
Starting with a low dose can help minimize these effects. It is important to understand that semaglutide is not right for everyone.
Who Can Take Semaglutide?
Semaglutide is only recommended for people with a BMI of 27kg/m2 or higher who have weight-related health issues, or those with a BMI of 30kg/m2 or more.
Who Should Not Take Semaglutide?
Semaglutide may not be suitable for everyone. It is especially advisable to avoid this product if you have certain medical conditions such as:
- Medullary thyroid cancer
- Gallbladder disease
- Pancreatitis
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
A detailed discussion with a primary care physician is necessary before considering semaglutide as part of a weight management program. They are well-equipped to understand your personal medical history, including any family characteristics, and can provide appropriate guidance on the most effective and safest treatment options
This is especially important if you deal with diabetes and are currently taking other medications, as your doctor can advise you on the safest and most effective combination of treatments for your specific condition
Holistic Approach to Weight Management
Semaglutide should be considered part of a combination approach to obesity management, which includes dietary modifications, exercise, and possibly a couple of other medications depending on individual health issues.
Consultation with a primary care physician is important for anyone considering semaglutide for weight loss. This ensures an appropriate approach, consideration of personal and family medical history, and any potential interactions with existing medications.
Recent Developments and Future Perspectives
In light of its growing popularity, recent developments in semaglutide research have focused on long-term efficacy and safety, as well as its potential impact on specific populations, like those with comorbid conditions such as heart disease or diabetes. As the scientific community continues to explore semaglutide’s full potential, it remains a promising tool in the battle against obesity.
